Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Strides Pharma...

    Strides Pharma re-enters injectable biz by infusing Rs 280 crore for controlling stake in Stelis Biopharma

    Farhat NasimWritten by Farhat Nasim Published On 2019-09-21T12:04:21+05:30  |  Updated On 13 Aug 2021 4:57 PM IST

    Bengaluru-based Strides has already invested USD 35 million (about Rs 245 crore) for a 43 per cent ownership in Stelis.


    New Delhi: Strides Pharma Science on Friday said its board has approved an additional investment of up to USD 40 million (about Rs 280 crore) over the next two years in Stelis Biopharma in a bid to take a controlling stake in the firm. Bengaluru-based Strides has already invested USD 35 million (about Rs 245 crore) for a 43 per cent ownership in Stelis.


    The company's board has approved an additional investment up to a maximum of USD 40 million over a period of 24 months for a controlling stake in Stelis, Strides Pharma Science said in a statement.

    "The proposed new investments will be a primary infusion into Stelis which will enable it to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides' re-entry into sterile injectables business," it added.

    Also Read: Strides Pharma infuses Rs 15.50 crore in Fair med for 70pc stake


    "With the infusion of up to USD 40 million by Strides and pending equity commitments from other partners, Stelis would have attained a critical size to break even at the operational level which is expected in the next 18 months," the company said.


    Besides Strides, the other principal shareholders of Stelis are Tenshi Life Sciences and GMS Holdings.


    Stelis has a research facility in Bengaluru and its current portfolio includes biosimilars produced from microbial production technology.

    Also Read: Strides Pharma acquires manufacturing plant in Florida for Rs 3.59 crore

    Bengalurubiopharmaceuticalcontrolling stakegms holdinginjectables businesspharmapharma newspharma news indiastelis biopharmasterile injectionsStridesstrides investmentStrides Pharmastrides pharma stakeTenshi Life
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok